News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Could Alnylam (ALNY) Have An Edge On This Smaller Biotech In Rare Disease?



7/11/2017 7:17:36 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Alnylam Pharmaceuticals (ALNY) could have an edge on Ionis Pharmaceuticals (IONS) in treating a rare disease that results in organ and system damage, an analyst said Monday.

Over the weekend, Ionis presented data from a Phase 3 trial showing its drug, inotersen, improved quality of life in TTR amyloidosis patients over 15 months vs. a placebo. In these patients, tissues called amyloid build up, causing damage to organs and systems.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES